The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Determinants of BRAF Mutations in Primary Melanomas
Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., Ono, T., Albertson, D. G., Pinkel, D., & Bastian, B. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg123 · Cited by 664 · cited 1×
“While mutations in BRAF are noted in up to 80% of primary cutaneous melanoma samples, BRAF is also mutated in the majority of benign melanocytic nevi (Brose et al., 2002; Kumar et al., 2003; Maldonado et al., 2003; Sasaki et al., 2004; Shinozaki et al., 2004; Thomas et al., 2004).”
BackgroundDisruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
Guldberg, P., Straten, P. T., Birck, A., Ahrenkiel, V., Kirkin, A. F., & Zeuthen, J. (1997) · PubMed · Cited by 480
PTEN signaling pathways in melanoma
Wu, H., Goel, V., & Haluska, F. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206451 · Cited by 480
Self-citationGenetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 467
Self-citationSatyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Belle, P. A. V., Elder, D. E., & Herlyn, M. (2003) · PubMed · Cited by 445
Omholt, K., Platz, A., Kanter, L., Ringborg, U. K., & Hansson, J. (2003) · PubMed · Cited by 399
Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation
Zhou, X.-P., Gimm, O., Hampel, H., Niemann, T., Walker, M. J., & Eng, C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64627-5 · Cited by 278
Dhawan, P., Singh, A. B., Ellis, D. L., & Richmond, A. J. (2002) · PubMed · Cited by 260
Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines
Tsao, H., Zhang, X., Benoit, E., & Haluska, F. G. (1998) · Oncogene · doi:10.1038/sj.onc.1201881 · Cited by 243
Self-citationRelative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Tsao, H., Zhang, X., Fowlkes, K., & Haluska, F. G. (2000) · PubMed · Cited by 234
Self-citationMutations of the BRAF Gene in Benign and Malignant Melanocytic Lesions
Yazdi, A. S., Palmedo, G., Flaig, M. J., Puchta, U., Reckwerth, A., Rütten, A., Mentzel, T., Hügel, H., Hantschke, M., Schmid-Wendtner, M.-H., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12559.x · Cited by 221
Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas
Shinozaki, M., Fujimoto, A., Morton, D. L., & Hoon, D. S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1169-3 · Cited by 212
BRAF alterations are associated with complex mutational profiles in malignant melanoma
Daniotti, M., Oggionni, M., Ranzani, T., Vallacchi, V., Campi, V., Di Stasi, D., Torre, G. D., Perrone, F., Luoni, C., Suardi, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207780 · Cited by 210
Molecular identification of latent precancers in histologically normal endometrium.
Mutter, G. L., Ince, T. A., Baak, J. P. A., Kust, G. A., Zhou, X. P., & Eng, C. (2001) · PubMed · Cited by 204
Whiteman, D. C., Zhou, X., Cummings, M. C., Pavey, S., Hayward, N. K., & Eng, C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10294 · Cited by 187
Molecular genetics of familial cutaneous melanoma.
Haluska, F. G., & Hodi, F. S. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.670 · Cited by 172
Self-citationUribe, P., Wistuba, I. I., & González, S. (2003) · American Journal of Dermatopathology · doi:10.1097/00000372-200310000-00001 · Cited by 142
High BRAF mutation frequency does not characterize all melanocytic tumor types
Saldanha, G. S., Purnell, D., Fletcher, A., Potter, L., Gillies, A., & Pringle, J. H. (2004) · International Journal of Cancer · doi:10.1002/ijc.20325 · Cited by 141
PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma
Tsao, H., Mihm, M. C., & Sheehan, C. E. (2003) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(03)02473-3 · Cited by 133
Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
Collisson, E. A., De, A., Suzuki, H., Gambhir, S. S., & Kolodney, M. S. (2003) · PubMed · Cited by 129
BRAF Point Mutations in Primary Melanoma Show Different Prevalences by Subtype
Sasaki, Y., Niu, C., Makino, R., Kudo, C., Sun, C., Watanabe, H. K., Matsunaga, J., Takahashi, K., Tagami, H., Aiba, S., et al. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22722.x · Cited by 91
Kumar, R., Angelini, S., & Hemminki, K. (2003) · Oncogene · doi:10.1038/sj.onc.1206909 · Cited by 90
Clinical significance of BRAF mutations in metastatic melanoma
Chang, D. Z., Panageas, K. S., Osman, I., Polsky, D., BUSAM, K. J., & Chapman, P. B. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-46 · Cited by 65
Tandem BRAF Mutations in Primary Invasive Melanomas
Thomas, N. E., Alexander, A. A., Edmiston, S. N., Parrish, E., Millikan, R. C., Berwick, M., Groben, P. A., Ollila, D. W., Mattingly, D., & Conway, K. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22523.x · Cited by 58
Absence of V599E BRAF mutations in desmoplastic melanomas
Davison, J. M., Rosenbaum, E., Barrett, T. L., Goldenberg, D., Hoque, M. O., Sidransky, D., & Westra, W. H. (2005) · Cancer · doi:10.1002/cncr.20861 · Cited by 56
Cited by
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Self-citationShain, A. H., & Bastian, B. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.37 · Cited by 896
NRAS mutation status is an independent prognostic factor in metastatic melanoma
Jakob, J. A., Bassett, R. L., Ng, C. S., Curry, J. L., Joseph, R. W., Alvarado, G. C., Rohlfs, M. L., Richard, J., Gershenwald, J. E., Kim, K. B., et al. (2012) · Cancer · doi:10.1002/cncr.26724 · Cited by 689
Self-citationAscierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640
Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 553
Metadata
- Authors
- Goel, V. K., Lazar, A. J. F., Warneke, C. L., Redston, M. S., & Haluska, F. G.
- Venue
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 126
- Issue
- 1
- Pages
- 154-160
- ISSN
- 0022-202X (ISSN-L)
- OpenAlex
- W2060317877
- Cited by
- 392
- References
- 29
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.